Arena Pharmaceutical’s Ralinepag Shows Promise in Treating PAH in Phase 2 Clinical Trial
Patients with pulmonary arterial hypertension (PAH) taking Arena Pharmaceuticals‘ next-generation therapy Ralinepag (APD811) showed significant improvements in blood flow and exercise capacity in a Phase 2 clinical trial. Results of the study (NCT02279160) will be presented at the American College…